$30B or $175B NASH is growing financial burden with $30
plus billion unmet market.
“NASH is sadly one of the fastest growing treatable major health problems on the planet right now, and analysts believe the resulting commercial opportunity could be as big as $20-35 billion annually by midway through this decade.”
https://www.marketwatch.com/press-release/the-race-is-heating-up-in-the-30-plus-billion-nash-treatment-space-mdgl-atrx-vktx-arwr-galt-mtcr-icpt-gild-2021-10-22?siteid=bigcharts&dist=bigcharts&tesla=y
“Younossi reported that 4.48% of the U.S. population (n = 11.2 million) had NASH in 2019 and of those with NASH, 70.1% had obesity.
From 2019 to 2040, he estimated that those classified as having obese NASH will have higher mortality when compared to non-obese NASH in all-cause mortality at 74.85% vs. 62.52% and cardiac-specific death at 28.26% vs. 8.51%. Liver-specific mortality, though, was slightly lower in the obesity group. These data should inform providers, payers, policy makers and other stakeholders to address the growing burden of NASH in the U.S.”
https://www.healio.com/news/hepatology/20211115/nash-in-us-estimated-to-cost-more-than-175-billion-over-next-2-decades